← FDA DRUG APPROVALS

FDA ANDA · ANDA202727

LANSOPRAZOLE

Sponsor: GLENMARK PHARMS

APPLICATION
ANDA202727
TYPE
ANDA
ORIGINAL APPROVAL
2012-05-18
LATEST ACTION
2024-11-26
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Over-the-counter

Products

LANSOPRAZOLEOver-the-counter
LANSOPRAZOLE 15MG · CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2024-11-26Labeling · Supplement 5 · standardAP
2024-11-26Labeling · Supplement 4 · standardAP
2012-05-18UNKNOWN · OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →